Biosimilars News

STAT News

Five years on, biosimilars need support from all health care players

Oncology Practice Management

Best Practices for Integrating Biosimilars into Your Oncology Practice

LinkedIn

Biosimilars – Let’s Not Throw the Baby Out with the Bathwater

Pharma Phorum

5 Years of Biosimilars in the US: What Have We Learned?

Fierce Pharma

Education and Strategy are Key to Nurturing Biosimilars for Success

Healio

Practice Champions Can Ensure Successful Integration of Biosimilars into Oncology Care

Center for Biosimilars

FDA Approves Amgen's Infliximab Biosimilar, Avsola

Generics Bulletin

US Biosimilars Market: AmerisourceBergen Q&A

AmerisourceBergen

Infographic: Physician Perspectives on Biosimilars

The center for biosimilars

FDA Approves Pfizer's Adalimumab Biosimilar, Abrilada

US Food & Drug Administration

Prescribing Biosimilar and Interchangeable Products

The Center for Biosimilars

In Survey, Physicians Rank Their Own Confidence as the Primary Barrier to Biosimilar Adoption

The Center for Biosimilars

Podcast: Strategies for Biosimilar Developers in a Litigious US Landscape

Goodwin

Court Upholds Validity of Enbrel® (etanercept) Patents in Immunex v. Sandoz Suit

The Center for Biosimilars

Oncology Group Says it Has Begun Treating Patients with Biosimilar Trastuzumab and Bevacizumab

Goodwin

Federal Circuit Declines to Block Sales of Amgen's KANJINTI (trastuzumab-anns) Before Resolving Genentech's Appeal

Goodwin

Genentech Appeals District Court's Refusal to Block Amgen's Trastuzumab and Bevacizumab Biosimilars

Goodwin

Federal Circuit Affirms Coherus Victory Over Amgen in Pegfilgrastim Patent Dispute

Goodwin

Amgen Sues Tanvex to Block Proposed Filgrastim Biosimilar

FiercePharma

Amgen Announces Availability of Two Biosimilars in US - Mvasi and Kanjinti

Goodwin

Genentech v. Hospira - Recap of July 11 Oral Argument

Goodwin

Biosimilar and Follow-on Biologic Development Updates

Seeking alpha

FDA OKs Amgen's Herceptin Biosimilar

Goodwin

Federal Circuit Affirms Sandoz's Victory Over Amgen in Filgrastim and Pegfilgrastim Biosimilar Patent Litigation

Goodwin

Samsung Bioepis Sued Regarding Its Recently-Approved Etanercept Biosimilar

The Center for Biosimilars

FDA Approves Samsung Bioepis' Etanercept Biosimilar, Eticovo

The Center for Biosimilars

PBM Says Its Biosimilars Strategy Led to 86% Use of Biosimilar Infliximab